Want to see DE:V3V full AI Analyst Report?
Top Page
VITA 34
(XETRA:V3V)
Select Model
Select Model
Rating:42Neutral
Price Target:
€3.00
▼(-50.41% Downside)
Action:Reiterated
Date:07/08/26
The score is weighed down primarily by weak financial performance—sharp TTM revenue contraction, ongoing net losses, and a highly leveraged balance sheet—despite improvements in margins and positive operating cash flow. Technicals add pressure with a clear downtrend (price below key moving averages and negative MACD), while valuation remains unattractive/unclear due to negative earnings and no dividend yield data.
Positive Factors
Recurring storage business
Vita 34’s core offering is long-term cryogenic storage with end-to-end logistics, testing and secure infrastructure. That model generates highly recurring, contract-driven revenues with strong customer stickiness and high switching costs, supporting predictable long-term cash inflows and lifetime customer value.
Negative Factors
Sharp revenue decline
A dramatic 67% TTM revenue drop materially reduces scale economics and undermines fixed-cost absorption. Sustained declines can erode customer acquisition returns, weaken market positioning, and prolong the timeline to restore profitable growth even if margins per unit have improved.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring storage business
Vita 34’s core offering is long-term cryogenic storage with end-to-end logistics, testing and secure infrastructure. That model generates highly recurring, contract-driven revenues with strong customer stickiness and high switching costs, supporting predictable long-term cash inflows and lifetime customer value.
Read all positive factors
VITA 34 (V3V) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€53.52M
Dividend YieldN/A
Average Volume (3M)1.65K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue Growth2.18%
EPS Growth50.91%
CountryDE
Employees783
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.33
Shares Outstanding17,640,104
10 Day Avg. Volume2,079
30 Day Avg. Volume1,645
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)14.70
Price to Sales (P/S)1.19
P/FCF Ratio-420.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€85.00M
VITA 34 Business Overview & Revenue Model
Company Description
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced ther...
How the Company Makes Money
null...
VITA 34 Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
45
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 88.17M | 82.18M | 77.06M | 68.94M | 28.42M |
| Gross Profit | 44.84M | 20.65M | 28.24M | 2.73M | 12.44M |
| EBITDA | 4.76M | -443.00K | 5.81M | -18.34M | 949.00K |
| Net Income | -6.30M | -12.14M | -1.86M | -27.39M | -3.93M |
Balance Sheet | |||||
| Total Assets | 168.26M | 152.74M | 158.36M | 151.51M | 177.95M |
| Cash, Cash Equivalents and Short-Term Investments | 11.88M | 18.46M | 17.42M | 18.23M | 35.26M |
| Total Debt | 23.51M | 18.10M | 21.57M | 28.18M | 32.32M |
| Total Liabilities | 162.84M | 139.83M | 135.58M | 135.66M | 136.00M |
| Stockholders Equity | 7.12M | 14.13M | 23.56M | 16.50M | 43.07M |
Cash Flow | |||||
| Free Cash Flow | -249.00K | 5.46M | 5.06M | -10.92M | 467.00K |
| Operating Cash Flow | 3.88M | 8.65M | 9.15M | -4.49M | 2.73M |
| Investing Cash Flow | -12.66M | -3.08M | -3.57M | -5.81M | 24.87M |
| Financing Cash Flow | 3.89M | -6.09M | -5.09M | -6.27M | -4.70M |
VITA 34 Technical Analysis
Negative
6.05
Price Trends
3.90
Negative
4.38
Negative
5.01
Negative
Market Momentum
-0.18
Positive
10.60
Positive
22.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Negative. The current price of 6.05 is above the 20-day moving average (MA) of 3.68, above the 50-day MA of 3.90, and above the 200-day MA of 5.01, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 10.60 is Positive, neither overbought nor oversold. The STOCH value of 22.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:V3V.
VITA 34 Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | €191.90M | 6.76 | 11.90% | 1.12% | 5.13% | 11.89% | |
60 Neutral | €304.54M | 22.11 | 2.69% | ― | 10.99% | -5.61% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | €218.08M | -69.11 | -1.37% | 2.71% | ― | ― | |
42 Neutral | €53.52M | -9.82 | -58.37% | ― | 2.18% | 50.91% |
* General Sector Average
DE:V3V
VITA 34
3.24
-1.62
-33.33%
DE:MED
MEDICLIN
4.04
1.11
37.98%
DE:SBS
STRATEC Biomedical
18.66
-8.11
-30.31%
DE:ILM1
Medios AG
12.16
-0.32
-2.56%
DE:HAEK
HAEMATO AG
13.10
2.28
21.03%
DE:7V0
Novogenia Holding AG
6.85
-0.14
-1.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.